Related references
Note: Only part of the references are listed.Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study
Esteban Fuentes-Valenzuela et al.
INFLAMMATORY BOWEL DISEASES (2023)
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases
Marthe Kirkesaether Brun et al.
JOURNAL OF INTERNAL MEDICINE (2023)
Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease
Ruben J. Colman et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
Failure to Achieve Target Drug Concentrations During Induction and Not HLA-DQA1*05 Carriage Is Associated With Antidrug Antibody Formation in Patients With Inflammatory Bowel Disease
Elizabeth A. Spencer et al.
GASTROENTEROLOGY (2022)
Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
Marthe Kirkesaether Brun et al.
JOURNAL OF INTERNAL MEDICINE (2022)
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
Johanna Elin Gehin et al.
BIODRUGS (2022)
Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Steven J. Bots et al.
BIODRUGS (2021)
Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease
Debora Curci et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)
Impact of the HLA-DQ1*05 alelle on the initial response to infliximab in patients with Inflammatory Bowel Disease
G. Suris Marin et al.
JOURNAL OF CROHNS & COLITIS (2021)
Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease
Aze Wilson et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease
Aleksejs Sazonovs et al.
GASTROENTEROLOGY (2020)
Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease
Amber Bangma et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab
Rebecca D. Powell Doherty et al.
GASTROENTEROLOGY (2020)
S0735 Carriage of HLA-DQA1*05 in Hispanic IBD Patients Is Common and Also Associated With Development of Antibodies to Anti-TNFs but Not Other Biologics
Stephanie Ioannou et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium
Signe Hassler et al.
PLOS MEDICINE (2020)
Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease
Gareth J. Walker et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Carriage of the HLA-DQA1*05 allele is associated with a high risk of loss of response to infliximab in patients with inflammatory bowel disease
J. Guardiola et al.
JOURNAL OF CROHNS & COLITIS (2019)
Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis
Niels Vande Casteele et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies
Omoniyi J. Adedokun et al.
JOURNAL OF CROHNS & COLITIS (2017)
Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease
Magali Lemaitre et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity
Takaya Moriyama et al.
NATURE GENETICS (2016)
Immunogenicity to infliximab is associated with HLA-DRB1
Thomas Billiet et al.
GUT (2015)
Inherited NUDT15 Variant Is a Genetic Determinant of Mercaptopurine Intolerance in Children With Acute Lymphoblastic Leukemia
Jun J. Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Assessing Bias in Studies of Prognostic Factors
Jill A. Hayden et al.
ANNALS OF INTERNAL MEDICINE (2013)
Immunogenicity of Monoclonal Antibodies Against Tumor Necrosis Factor Used in Chronic Immune-Mediated Inflammatory Conditions Systematic Review and Meta-analysis
Jose Ramon Maneiro et al.
JAMA INTERNAL MEDICINE (2013)
Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease
Ingrid Ordas et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
Geertje M. Bartelds et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
GRADE guidelines: 3. Rating the quality of evidence
Howard Balshem et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews
JB Reitsma et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2005)
Share Paper
